Glaukos (GKOS) Expected to Post Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) is expected to issue its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Glaukos to post earnings of ($0.0964) per share and revenue of $168.04 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The firm’s quarterly revenue was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. On average, analysts expect Glaukos to post ($0.32) EPS for the current fiscal year and $0.55 EPS for the next fiscal year.

Glaukos Stock Up 4.0%

Shares of Glaukos stock opened at $173.71 on Wednesday. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a 50-day simple moving average of $171.89 and a two-hundred day simple moving average of $149.12. Glaukos has a one year low of $73.16 and a one year high of $191.62.

Insiders Place Their Bets

In related news, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert Kliman sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 83,025 shares of company stock worth $14,950,006 over the last quarter. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GKOS. Needham & Company LLC raised their price target on shares of Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Citigroup boosted their price objective on shares of Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. UBS Group started coverage on shares of Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price for the company. Finally, Stifel Nicolaus increased their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $181.43.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.